Longitudinal Profiling of Cervical Cancers Reveals Therapy-Induced Vulnerabilities Beyond the Checkpoint

Area of Science:

• Oncology
• Cancer Research
• Molecular Biology

Background:

• Cervical cancer patients exhibit variable responses to chemoradiation therapy (CRT).
• Understanding molecular drivers of treatment response is crucial for patient stratification.
• Identifying novel therapeutic targets can improve outcomes for non-responsive patients.

Purpose of the Study:

• To characterize the molecular and cellular reprogramming induced by CRT in cervical cancer.
• To identify molecular features associated with treatment response and resistance.
• To evaluate MDM2 as a potential therapeutic target in combination with radiation.

Main Methods:

• Integrated multiomic analyses of longitudinal patient cohorts.
• Analysis of tumor microenvironment immune cell infiltration.
• Assessment of DNA damage response pathways in tumor cells.
• Xenograft models using treatment-naïve and CRT-exposed patient tumors.

Main Results:

• CRT reshapes the tumor microenvironment, shifting immune infiltration from lymphoid-dominant to myeloid-dominant.
• MDM2-dependent DNA damage response is induced specifically in tumor cells post-CRT.
• MDM2 inhibition combined with radiation enhances treatment response, especially in therapy-resistant xenografts.

Conclusions:

• MDM2 is a therapy-induced target identified through unbiased multiomic analysis.
• Targeting MDM2 may overcome resistance to chemoradiation in cervical cancer.
• Understanding intervention timing and patient selection is key for integrating novel therapies.